25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients

11Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and aim: The impact of 25-OH vitamin D on sustained viral response (SVR) to antiviral therapy and on fibrosis progression in hepatitis C is debated. We assessed the impact of 25-OH vitamin D concentration on the efficacy of antiviral therapy in naïve genotype 1 hepatitis C virus (HCV)-infected patients. Methods: The study population consisted of treatment-naïve genotype 1 patients enrolled in a randomised controlled trial. A total of 516 patients received peginterferon α-2a 180 µg/week plus ribavirin 800 mg/day for 24 weeks. There were 349 patients with undetectable HCV RNA (<50 IU/ml) at week 24 (W24) who were randomised to continue dual therapy (n = 173) or to continue peginterferon alone (n = 176) until week 48. 25-OH vitamin D concentration was measured at baseline in frozen serum. Results: A total of 461 patients could be analysed for virologic response at W24, and 285 (119 non-responders at W24 + 166 responders who continued dual therapy until W48) for the impact of SVR. There were 487 patients who could be analysed for fibrosis progression. Metavir fibrosis scores (centralised analysis) were: F1 30%, F2 34%, F3 27% and F4 9%. Median 25-OH vitamin D concentrations were similar in virologic responders (13.5 ng/ml) and in non-responders at W24 (12.6 ng/ml), as well as in patients with SVR (12.8 ng/ml) and without SVR (12.8 ng/ml, 3.99) at W72. Median 25-OH vitamin D concentrations were: F1: 14.30 ng/ml, F2: 13.50 ng/ml, F3: 13.30 ng/ml and F4: 12.80 ng/ml. Conclusion: In this study, 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

References Powered by Scopus

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

3188Citations
N/AReaders
Get full text

Boceprevir for untreated chronic HCV genotype 1 infection

2317Citations
N/AReaders
Get full text

Telaprevir for previously untreated chronic hepatitis C virus infection

2218Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immune modulatory effects of vitamin d on viral infections

86Citations
N/AReaders
Get full text

The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases

48Citations
N/AReaders
Get full text

Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review

46Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Belle, A., Gizard, E., Conroy, G., Lopez, A., Bouvier-Alias, M., Rouanet, S., … Bronowicki, J. P. (2017). 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. United European Gastroenterology Journal, 5(1), 69–75. https://doi.org/10.1177/2050640616640157

Readers over time

‘17‘18‘19‘20‘21‘22‘23036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

56%

Professor / Associate Prof. 3

33%

Researcher 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

54%

Agricultural and Biological Sciences 4

31%

Nursing and Health Professions 1

8%

Social Sciences 1

8%

Save time finding and organizing research with Mendeley

Sign up for free
0